Translational research study of NIVOlumab RE-adminiTration for UnResectable/recurreNt gaStric cancer

Translational research study of NIVOlumab RE-adminiTration for UnResectable/recurreNt gaStric cancer - NIVO-RETURNS TR

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051044

Enrollment

200

Registered

2023-05-12

Start date

2023-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable/recurrent gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: According to the study "Prospective observational study of efficacy and safety in re-administration of nivolumab for unresectable advanced/recurrent gastric cancer"

Exclusion criteria

Exclusion criteria: According to the study "Prospective observational study of efficacy and safety in re-administration of nivolumab for unresectable advanced/recurrent gastric cancer"

Design outcomes

Primary

Measure	Time frame
FCM analysis FCM will use Immunity Research Inc.'s measurement kit to evaluate the following factors, and search for factors related to OS, PFS, and RR. CD4: CD25, CD62L, CXCR3, CCR4, CCR6, Th1, Th7R (Th1/Th17, CCR6 SP), Th17 CD8: CCR7, CD45RA, EM, EMRA, CM naive	—

Countries

Japan

Contacts

Public ContactHiroyuki Kodama

Aichi Cancer Center Department of Clinical Oncology

h.kodama@aichi-cc.jp052-762-6111

Outcome results